...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Effect of Ondansetron on Prevention of Ventilator Associated Pneumonia in Intensive Care Unit Patients in Kashani Hospital in 2013 UC05-UC08
【24h】

Effect of Ondansetron on Prevention of Ventilator Associated Pneumonia in Intensive Care Unit Patients in Kashani Hospital in 2013 UC05-UC08

机译：恩丹西酮对卡珊妮医院2013年重症监护病房患者呼吸机相关性肺炎的预防作用UC05-UC08

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Ventilator Associated Pneumonia (VAP) is the second most common infection with high mortality (24-50%). Ondansetron is a reliable and safe drug and it is currently used in the prevention of nausea and vomiting and has no side effects.Aim: The aim of the present study was to examine the effect of ondansetron on prevention of VAP in Intensive Care Unit (ICU) patients.Materials and Methods: The present study was a randomized clinical trial study (IRCT201406156480N6), carried out at Kashani Hospital, Iran, in 2013 on 80 patients aged from 15-65 years. The patients were randomly allocated to two groups: Case group (n=40) and Control group (n=40). The patients in first group were injected with 4 mg ondansetron, twice daily for five days. The patients of other group were injected with distilled water as placebo. The presence of VAP was assessed in the two groups. The collected data were analysed by SPSS software through Fisher-exact test.Results: Eleven (13.8%) patients were diagnosed with VAP. Among them, 9 (81.8%) patients were male and 2 (18.2%) patients were female. The incidence of VAP in Case group was 5 (12.5%) patients and in Control group was 6 (15%) patients (p>0.05). Results showed that VAP in Case group was less prevalent than that in the Control group, but this difference was not significant.Conclusion: The study did not find an association between ondansetron administration and reduction in VAP incidence; vomiting alone may not be leading to VAP, instead silent micro aspirations may be the cause of it. None of the factor such as age, sex, weight, smoking, drug addiction was found significantly related to VAP. Only variable found related was comorbidity.
机译：简介：呼吸机相关性肺炎（VAP）是第二常见的高死亡率感染（24-50％）。昂丹司琼是一种安全可靠的药物，目前用于预防恶心和呕吐，并且没有副作用。目的：本研究的目的是研究昂丹司琼对重症监护室（ICU）预防VAP的作用。材料与方法：本研究是一项随机临床试验研究（IRCT201406156480480N6），于2013年在伊朗的Kashani医院进行，研究对象是80名年龄在15-65岁之间的患者。将患者随机分为两组：病例组（n = 40）和对照组（n = 40）。第一组患者每天两次注射4毫克恩丹西酮，持续5天。另一组患者注射蒸馏水作为安慰剂。两组均评估了VAP的存在。通过SPSS软件通过Fisher精确检验对收集的数据进行分析。结果：11例（13.8％）患者被诊断为VAP。其中，男性9例（81.8％），女性2例（18.2％）。病例组中VAP的发生率为5（12.5％）患者，对照组中为6（15％）（P> 0.05）。结果表明，病例组的VAP较对照组的流行率低，但这种差异并不显着。结论：本研究未发现恩丹西酮给药与VAP发生率降低之间存在关联。单独呕吐可能不会导致VAP，相反，无声的微小吸入可能是导致VAP的原因。没有发现诸如年龄，性别，体重，吸烟，吸毒成瘾等因素与VAP显着相关。仅发现相关的变量是合并症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号